Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

NCT Number	NCT07624526
Lead Sponsor	Emory University Collaborators: Vertex Pharmaceuticals Incorporated
Conditions	Knee Arthritis, Knee Osteoarthritis
Enrollment	75 participants
Start Date	2026-07
Primary Completion	2028-08 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-03